eg Working with Cellaura on Fluorescent Screening Drug-Discovery Instrument
News Oct 23, 2012
Their technology uses high quality fluorescent G-protein-coupled receptor ligands for molecular pharmacology and cell imaging. eg technology is working with the team at CellAura to develop their perfusion system into a commercially viable instrument.
To date, eg has carried out several phases of work to define the instrument specification, provide conceptual CAD of the instrument and, most recently, to design and build a breadboard prototype of the fluid handling system to test and de-risk the proposed architecture and fluid-handling software.
Dai Hayward, CellAura's Chief Executive, said "Working with eg technology has been a pleasure. Their project team has listened patiently to discern our real requirements and then shaped our thinking to ensure that these needs have been met in a thoroughly professional manner."
CellAura are aiming to trial beta systems with selected partners before the end of 2012, with the first commercial units available early in 2013.
Tailor-made Protein Fights Several Species of BacteriaNews
As resistance to existing antibiotics increases, new approaches to serious bacterial infections are needed. Now researchers have investigated one such alternative.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE